Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yvette Drew

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
British Journal of Cancer|December 17, 2015
The development of PARP inhibitors in ovarian cancer: from bench to bedsideYvette Drew
Current Opinion in Obstetrics & Gynecology|November 26, 2009
The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancerYvette Drew, Ruth Plummer
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|November 27, 2009
PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applicationsYvette Drew, Ruth Plummer
Annals of the New York Academy of Sciences|October 8, 2008
The potential of PARP inhibitors in genetic breast and ovarian cancersYvette Drew, Hilary Calvert
Cancers|January 11, 2022
Tipping Growth Inhibition into Apoptosis by Combining Treatment with MDM2 and WIP1 Inhibitors in p53<sup>WT</sup> Uterine LeiomyosarcomaVictoria Chamberlain, Yvette Drew, John Lunec
Gynecologic Oncology Reports|July 22, 2024
Challenges in PARP inhibitor therapy: A case of Olaparib-induced liver injury and successful rechallenge with NiraparibKai Zhu, Yvette Drew, Saumya Jayakumar
European Journal of Cancer (Oxford, England : 1990)|April 12, 2016
Homologous recombination deficiency and ovarian cancerJonathan A Ledermann, Yvette Drew, Rebecca S Kristeleit
Pharmacology & Therapeutics|December 15, 2019
Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?Alice Bradbury, Sally Hall, Nicola Curtin, et al.
Nature Reviews. Drug Discovery|November 12, 2024
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implicationsYvette Drew, Frank T Zenke, Nicola J Curtin
International Journal of Women'S Health|January 2, 2018
Emerging treatment options for ovarian cancer: focus on rucaparibLavanya Mariappan, Xue Yan Jiang, Josie Jackson, et al.
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
British Journal of Cancer|December 17, 2015
The development of PARP inhibitors in ovarian cancer: from bench to bedsideYvette Drew
Current Opinion in Obstetrics & Gynecology|November 26, 2009
The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancerYvette Drew, Ruth Plummer
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|November 27, 2009
PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applicationsYvette Drew, Ruth Plummer
Annals of the New York Academy of Sciences|October 8, 2008
The potential of PARP inhibitors in genetic breast and ovarian cancersYvette Drew, Hilary Calvert
Cancers|January 11, 2022
Tipping Growth Inhibition into Apoptosis by Combining Treatment with MDM2 and WIP1 Inhibitors in p53<sup>WT</sup> Uterine LeiomyosarcomaVictoria Chamberlain, Yvette Drew, John Lunec
Gynecologic Oncology Reports|July 22, 2024
Challenges in PARP inhibitor therapy: A case of Olaparib-induced liver injury and successful rechallenge with NiraparibKai Zhu, Yvette Drew, Saumya Jayakumar
European Journal of Cancer (Oxford, England : 1990)|April 12, 2016
Homologous recombination deficiency and ovarian cancerJonathan A Ledermann, Yvette Drew, Rebecca S Kristeleit
Pharmacology & Therapeutics|December 15, 2019
Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?Alice Bradbury, Sally Hall, Nicola Curtin, et al.
Nature Reviews. Drug Discovery|November 12, 2024
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implicationsYvette Drew, Frank T Zenke, Nicola J Curtin
International Journal of Women'S Health|January 2, 2018
Emerging treatment options for ovarian cancer: focus on rucaparibLavanya Mariappan, Xue Yan Jiang, Josie Jackson, et al.
Pageof 5